Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:affiliatedWith |
gptkb:National_Institutes_of_Health
|
| gptkbp:campusFacilities |
gptkb:University_of_California
|
| gptkbp:chemicalFormula |
stable under normal conditions
thiazole derivatives lipophilic contains thiazole ring C20H22N2O2S binds to active site of enzyme |
| gptkbp:class |
antiviral agents
|
| gptkbp:clinicalTrials |
gptkb:United_States
Phase III Phase I promising efficacy |
| gptkbp:collaborations |
international collaboration
|
| gptkbp:compatibleWith |
moderate bioavailability
|
| gptkbp:complications |
potential liver toxicity
|
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:dissolved |
soluble in DMSO
poorly soluble in water |
| gptkbp:drugInterdiction |
yes
|
| gptkbp:funding |
federal grants
|
| https://www.w3.org/2000/01/rdf-schema#label |
DX517
|
| gptkbp:impact |
fatigue
headache nausea |
| gptkbp:is_aimed_at |
HIV/AIDS
|
| gptkbp:lifespan |
approximately 6 hours
|
| gptkbp:market |
not yet marketed
|
| gptkbp:notableWork |
high potential for HIV treatment.
|
| gptkbp:number_of_stages |
Phase II
|
| gptkbp:nutritionalValue |
liver metabolism
|
| gptkbp:operational_status |
clinical trial
|
| gptkbp:origin |
N-(2-(4-(4-(dimethylamino)phenyl)thiazol-2-yl)thiazol-4-yl)ethyl)benzamide
|
| gptkbp:patentAssignee |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publicationDate |
2020
|
| gptkbp:publications |
published in peer-reviewed journal
|
| gptkbp:related_to |
antiretroviral therapy
high affinity for HIV-1 reverse transcriptase |
| gptkbp:releaseYear |
2015
|
| gptkbp:research |
drug resistance
|
| gptkbp:research_areas |
infectious diseases
antiviral_drug_development |
| gptkbp:research_focus |
HIV treatment
first human trials completed improve HIV treatment options |
| gptkbp:researchAndDevelopment |
further studies needed
|
| gptkbp:researchInterest |
conducted in vitro
conducted in vivo |
| gptkbp:route |
oral
|
| gptkbp:safety_features |
under investigation
|
| gptkbp:sponsor |
pharmaceutical company
|
| gptkbp:targets |
HIV reverse transcriptase
HIV-1 |
| gptkbp:team |
led_by_Dr._Smith
|
| gptkbp:triggerType |
inhibitor of HIV-1 reverse transcriptase
|